Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion
Actelion (SWX:ATLN) Leerink Andrew Fein New Market outperform
Fein estimates FY04 and FY05 EPS of CHF3.24 ($2.59) and CHF4.92 ($3.94), respectively.
Angiotech (TSE:ANP; ANPI) RBC Capital Markets

Read the full 409 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers